



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

EVI2A siRNA (m): sc-144962

BACKGROUND

EVI2A (ecotropic viral integration site 2A), also known as EVDA or EVI2, is a 236 amino acid single-pass type I membrane protein that belongs to the EVI2A family. Localizing to the membrane, EVI1A may act as a cell-surface receptor by forming a complex with itself or other proteins within the membrane. Existing as two alternatively spliced isoforms, the gene encoding EVI2A maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes.

REFERENCES

1. O'Connell, P., Viskochil, D., Buchberg, A.M., Fountain, J., Cawthon, R.M., Culver, M., Stevens, J., Rich, D.C., Ledbetter, D.H. and Wallace, M. 1990. The human homolog of murine Evi-2 lies between two von Recklinghausen neurofibromatosis translocations. *Genomics* 7: 547-554.
2. Cawthon, R.M., O'Connell, P., Buchberg, A.M., Viskochil, D., Weiss, R.B., Culver, M., Stevens, J., Jenkins, N.A., Copeland, N.G. and White, R. 1990. Identification and characterization of transcripts from the neurofibromatosis 1 region: the sequence and genomic structure of EVI2 and mapping of other transcripts. *Genomics* 7: 555-565.
3. Buchberg, A.M., Bedigian, H.G., Jenkins, N.A. and Copeland, N.G. 1990. Evi-2, a common integration site involved in murine myeloid leukemogenesis. *Mol. Cell. Biol.* 10: 4658-4666.
4. Viskochil, D., Cawthon, R., O'Connell, P., Xu, G.F., Stevens, J., Culver, M., Carey, J. and White, R. 1991. The gene encoding the oligodendrocyte-myelin glycoprotein is embedded within the neurofibromatosis type 1 gene. *Mol. Cell. Biol.* 11: 906-912.
5. Xu, W., Liu, L. and Ponder, B.A. 1991. A BamHI polymorphism in the human EVI2A gene (human homolog of the murine gene Evi-2). *Nucleic Acids Res.* 19: 2520.
6. Largaespada, D.A., Shaughnessy, J.D., Jenkins, N.A. and Copeland, N.G. 1995. Retroviral integration at the Evi-2 locus in BXH-2 myeloid leukemia cell lines disrupts Nf1 expression without changes in steady-state Ras-GTP levels. *J. Virol.* 69: 5095-5102.
7. Rasmussen, S.A., Ho, V.T., Colman, S.D., Abernathy, C.R. and Wallace, M.R. 1996. A multiplex-PCR test for EVI2A and EVI2B polymorphisms within the human NF1 gene. *Mamm. Genome* 7: 233-234.
8. Soussi, T., Dehouche, K. and Beroud, C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum. Mutat.* 15: 105-113.
9. Piura, B., Rabinovich, A. and Yanai-Inbar, I. 2001. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 97: 241-244.

CHROMOSOMAL LOCATION

Genetic locus: Evi2a (mouse) mapping to 11 B5.

PRODUCT

EVI2A siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see EVI2A shRNA Plasmid (m): sc-144962-SH and EVI2A shRNA (m) Lentiviral Particles: sc-144962-V as alternate gene silencing products.

For independent verification of EVI2A (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-144962A, sc-144962B and sc-144962C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

EVI2A siRNA (m) is recommended for the inhibition of EVI2A expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor EVI2A gene expression knockdown using RT-PCR Primer: EVI2A (m)-PR: sc-144962-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.